METTL16 Antagonizes MRE11-mediated DNA End Resection and Confers Synthetic Lethality to PARP Inhibition in Pancreatic Ductal Adenocarcinoma
Xiangyu Zeng,Fei Zhao,Gaofeng Cui,Yong Zhang,Rajashree A. Deshpande,Yuping Chen,Min Deng,Jake A. Kloeber,Yu Shi,Qin Zhou,Chao Zhang,Jing Hou,Wootae Kim,Xinyi Tu,Yuanliang Yan,Zhijie Xu,Lifeng Chen,Huanyao Gao,Guijie Guo,Jiaqi Liu,Qian Zhu,Yueyu Cao,Jinzhou Huang,Zheming Wu,Shouhai Zhu,Ping Yin,Kuntian Luo,Georges Mer,Tanya T. Paull,Jian Yuan,Kaixiong Tao,Zhenkun Lou
DOI: https://doi.org/10.1038/s43018-022-00429-3
IF: 22.7
2022-01-01
Nature Cancer
Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Characterization of genetic alterations will improve our understanding and therapies for this disease. Here, we report that PDAC with elevated expression of METTL16, one of the 'writers' of RNA N6-methyladenosine modification, may benefit from poly-(ADP-ribose)-polymerase inhibitor (PARPi) treatment. Mechanistically, METTL16 interacts with MRE11 through RNA and this interaction inhibits MRE11's exonuclease activity in a methyltransferase-independent manner, thereby repressing DNA end resection. Upon DNA damage, ATM phosphorylates METTL16 resulting in a conformational change and autoinhibition of its RNA binding. This dissociates the METTL16-RNA-MRE11 complex and releases inhibition of MRE11. Concordantly, PDAC cells with high METTL16 expression show increased sensitivity to PARPi, especially when combined with gemcitabine. Thus, our findings reveal a role for METTL16 in homologous recombination repair and suggest that a combination of PARPi with gemcitabine could be an effective treatment strategy for PDAC with elevated METTL16 expression.